Chonnam Med J.  2017 May;53(2):118-126. 10.4068/cmj.2017.53.2.118.

Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat

• Khanjarsim V
• Karimi J
• Khodadadi
• Mohammadalipour A
• Goodarzi M
• Solgi G
• Hashemnia

• KMID: 2379284
• DOI: http://doi.org/10.4068/cmj.2017.53.2.118

Abstract

Nilotinib as a tyrosine kinase inhibitor has been recently used to improve the liver fibrosis process, but the exact mechanisms still require further clarification. In this study, we investigated the anti-fibrotic effects of Nilotinib via RAGE/HMGB1axis and antioxidant mechanisms. This experimental study was performed in the Hamadan University of Medical Sciences, Iran, from May 2015 to December 2016. Liver fibrosis was induced in Wistar male rats by CCL₄. Rats were gavaged daily with Nilotinib (10 mg/kg). RAGE, HMGB1, TNF-α and TGF-β mRNA expression were evaluated by quantitative RT-PCR. TNF-α protein levels were measured using the immunoassay method. Thiol groups, carbonyl groups, nitric oxide levels and glutathione peroxidase activity were measured by spectrophotometric methods.The results showed that Nilotinib decreased TNF-α, TGF-β, RAGE and HMGB1 mRNA expression (p<0.001) in the liver tissues of the fibrosis group. Nilotinib also decreased carbonyl groups and nitric oxide levels and increased thiol groups and glutathione peroxidase activity in the fibrosis groups. The histopathological changes were found to be attenuated by Nilotinib. In conclusion, Nilotinib can improve liver fibrosis and open new mechanisms of the anti-fibrotic properties of Nilotinib.

Keyword

HMGB1 Protein; Liver Cirrhosis; Nitric Oxide; Rats

MeSH Terms

Animals
Fibrosis
Gene Expression*
Glutathione Peroxidase
HMGB1 Protein
Humans
Immunoassay
Iran
Liver Cirrhosis*
Liver*
Male
Methods
Nitric Oxide
Oxidative Stress*
Protein-Tyrosine Kinases
Rage
Rats*
RNA, Messenger
Glutathione Peroxidase
HMGB1 Protein
Nitric Oxide
Protein-Tyrosine Kinases
RNA, Messenger

Figure

• 

  FIG. 1 Effectsof Nilotinib on RAGE mRNA levels (A) and HMGB1 mRNA levels (B) in the liver tissues of rats with liver fibrosis. C: Control normal, O: Olive control group, CN: Nilotinib control group, F: Liver fibrosis group, FN: Liver fibrosis treated with Nilotinib (10 mg/kg body weight), the data represent mean±SD. *ap<0.001 versus groups C, O and CN.*bp<0.001 versus group F.

• 

  FIG. 2 Effectsof Nilotinib on TNF-α protein levels (A), TGF-β1 mRNA levels (B) and TNF-α mRNA levels (C), in the liver tissues of rats with liver fibrosis. C: Control normal, O: Olive control group, CN: Nilotinib control group, F: Liver fibrosis group, FN: Liver fibrosis treated with Nilotinib (10 mg/kg body weight), the data represent mean±SD. ap<0.001 versus groups C, O and CN.bp<0.001 versus group F.

• 

  FIG. 3 Effects of Nilotinib on oxidative stress stutus in the liver tissues of rats with liver fibrosis. Hepatic thiol group (A), Glutathion peroxidase (B) and carbonyl group (C) levels after 12 weeks in the different groups. C: Control normal, O: Olive control group, CN: Nilotinib control group, F: Liver fibrosis group, FN: Liver fibrosis treated with Nilotinib (10 mg/kg body weight), the data represent mean±SD. ap<0.001 versus groups C, O and CN.*bp<0.001 versus group F. cp<0.05 versus group F.

• 

  FIG. 4 Effects of Nilotinib on nitric oxide (NO) levels in the liver tissues of rats with liver fibrosis. C: Control normal, O: Olive control group, CN: Nilotinib control group, F: Liver fibrosis group, FN: Liver fibrosis treated with Nilotinib (10 mg/kg body weight), the data represent mean±SD. ap<0.001 versus groups C, O and CN. bp<0.001 versus group F.

• 

  FIG. 5 Pathological features of rat liver tissue in different groups (HE staining; Bar=100 µm). (A) severe macrovesicular steatosis with many hepatocytes showing ballooning degeneration (stars) in CCl4 group; (B) mild macrovesicular steatosis (star) in CCl4+nilotinib group; (C) severe infiltration of mononuclear cells around the portal area (arrow) in CCl4 group; (D) mild infiltration of mononuclear cells around the portal area (arrow) in CCl4+nilotinib group; (E) CCl4 group; severe focal necrosis in CCl4 group; (F) mild focal necrosis in CCl4+nilotinib group.

• 

  FIG. 6 Masson's trichrome staining of hepatic tissue for collagen in different groups. (A) control group; no fibrosis; (B) CCL4 group; fibrosis expansion of the portal area with marked bridging as well as portal to central; (C) marked reduction of collagen deposition in CCl4+ nilotinib group (Bar=320 µm).

Reference

1. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010; 10:40.

2. Wang P, Koyama Y, Liu X, Xu J, Ma HY, Liang S, et al. Promising therapy candidates for liver fibrosis. Front Physiol. 2016; 7:47.

3. Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs. 2015; 24:309–327.

4. Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015; 22:512–518.

5. Khazaei M, Karimi J, Sheikh N, Goodarzi MT, Saidijam M, Khodadadi I, et al. Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) expression and oxidative stress in the liver of rats with type 2 diabetes. Phytother Res. 2016; 30:66–71.

6. Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013; 1833:101–109.

7. Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol. 2012; 57:160–167.

8. Basta G, Navarra T, De Simone P, Del Turco S, Gastaldelli A, Filipponi F. What is the role of the receptor for advanced glycation end products-ligand axis in liver injury? Liver Transpl. 2011; 17:633–640.

9. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology. 2001; 34:943–952.

10. Lohwasser C, Neureiter D, Popov Y, Bauer M, Schuppan D. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol. 2009; 15:5789–5798.

11. Qu K, Huang Z, Lin T, Liu S, Chang H, Yan Z, et al. New Insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials. Front Pharmacol. 2016; 6:300.

12. Shiha GE, Abu-Elsaad NM, Zalata KR, Ibrahim TM. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight. Clin Exp Pharmacol Physiol. 2014; 41:788–797.

13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–254.

14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–408.

15. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990; 186:464–478.

16. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994; 233:380–385.

17. Saneyasu T, Akhtar R, Sakai T. Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis. Biomed Res Int. 2016; 2016:2646212.

18. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010; 7:425–436.

19. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, et al. Inhibition of PDGF, TGF-XMLLink_XYZ, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol. 2011; 55:612–625.

20. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology. 2004; 39:422–432.

21. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, et al. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol. 2006; 21:682–688.

22. Xia JR, Liu NF, Zhu NX. Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci. 2008; 9:638–661.

23. Kao YH, Jawan B, Goto S, Hung CT, Lin YC, Nakano T, et al. High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant Proc. 2008; 40:2704–2705.

24. Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol. 2011; 17:4090–4098.

25. Arriazu E, Ge X, Leung TM, Magdaleno F, Lopategi A, Lu Y, et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut. 2016; DOI: 10.1136/gutjnl-2015-310752. [Epub ahead of print].

26. Ge X, Antoine DJ, Lu Y, Arriazu E, Leung TM, Klepper AL, et al. High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem. 2014; 289:22672–22691.

27. Mohammadalipour A, Karimi J, Khodadadi I, Solgi G, Hashemnia M, Sheikh N, et al. Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism. Immunopharmacol Immunotoxicol. 2017; 39:19–27.

28. Sánchez-Valle V, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem. 2012; 19:4850–4860.

29. Shaker ME. Nilotinib interferes with the signalling pathways implicated in acetaminophen hepatotoxicity. Basic Clin Pharmacol Toxicol. 2014; 114:263–270.

30. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res. 2010; 162:95–109.